Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Leon A Adams

Showing results (1-10 of 203) with videos related to

Pageof 21
Sort By:
Hepatology International|February 21, 2019
End-points for drug treatment in NASHLeon A Adams
Endocrine Research|December 20, 2007
Nonalcoholic fatty liver disease and diabetes mellitusLeon A Adams
Nature Reviews. Gastroenterology & Hepatology|February 11, 2015
NAFLD. Accurate quantification of hepatic fat--is it important?Leon A Adams
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|December 3, 2022
Metabolic Health and Outcomes in Fatty Liver: Does a Name Change Matter?Leon A Adams
Journal of Gastroenterology and Hepatology|January 5, 2011
Biomarkers of liver fibrosisLeon A Adams
Hepatology (Baltimore, Md.)|May 28, 2011
Mortality in nonalcoholic fatty liver disease: clues from the Cremona studyLeon A Adams
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|June 27, 2021
The Weighty Issue of Treating Obesity in Patients With Nonalcoholic Fatty Liver DiseaseLeon A Adams
Hepatology International|May 11, 2019
Correction to: End-points for drug treatment in NASHLeon A Adams
Current Opinion in Endocrinology, Diabetes, and Obesity|February 13, 2023
Cardiovascular disease in metabolic-associated fatty liver diseaseLeon A Adams
The American Journal of Gastroenterology|November 26, 2003
Vitamins E and C for the treatment of NASH: duplication of results but lack of demonstration of efficacyLeon A Adams, Paul Angulo
Pageof 21

Showing results (1-10 of 203) with videos related to

Sort By:
Pageof 21
Hepatology International|February 21, 2019
End-points for drug treatment in NASHLeon A Adams
Endocrine Research|December 20, 2007
Nonalcoholic fatty liver disease and diabetes mellitusLeon A Adams
Nature Reviews. Gastroenterology & Hepatology|February 11, 2015
NAFLD. Accurate quantification of hepatic fat--is it important?Leon A Adams
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|December 3, 2022
Metabolic Health and Outcomes in Fatty Liver: Does a Name Change Matter?Leon A Adams
Journal of Gastroenterology and Hepatology|January 5, 2011
Biomarkers of liver fibrosisLeon A Adams
Hepatology (Baltimore, Md.)|May 28, 2011
Mortality in nonalcoholic fatty liver disease: clues from the Cremona studyLeon A Adams
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|June 27, 2021
The Weighty Issue of Treating Obesity in Patients With Nonalcoholic Fatty Liver DiseaseLeon A Adams
Hepatology International|May 11, 2019
Correction to: End-points for drug treatment in NASHLeon A Adams
Current Opinion in Endocrinology, Diabetes, and Obesity|February 13, 2023
Cardiovascular disease in metabolic-associated fatty liver diseaseLeon A Adams
The American Journal of Gastroenterology|November 26, 2003
Vitamins E and C for the treatment of NASH: duplication of results but lack of demonstration of efficacyLeon A Adams, Paul Angulo
Pageof 21